Unfortunately I agree. ADXS has never even communicated what would trigger those milestones. Some could be years away based on even good clinical progress. As I stated before they are probably worth at most .10 cents on the dollar in today's money.
Perception is also a significant component of PPS valuation, especially in Biotech. And right now the overall perception of ADXS (fair or not) is very low. That's why the market is barely assigning value to anything inside the company. As absurd (or maybe even unfair) a valuation is of only $50M for all non-cash assets, programs, and IP...this is where management matters and why good management is so important, especially in Biotech.
All Biotechs come under assault at one time or another, and the quality of management can make a major impact on how that company weathers the storm and emerges from it.
I am a shareholder based on the science and continue to hope for the best. But unfortunately we have had extremely limited communications from an interim CEO who is entering his 9th month on the job, still no CMO, no partnership (yet), and a BOD that apparently answers to no one regardless of how many mistakes some of them have made over the last decade.
I think the idea that this specific management crew and BOD could ever get the value of this company to $6B someday is not realistic. But I still hold out hope for a $750M to $1B valuation in time.
News 
Market Data 
Discover 
AI
